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A B S T R A C T   
Purpose: Phenylketonuria (PKU) can be effectively treated with the use of a low-phenylalanine diet. However, 
some patients become overweight despite proper dietary treatment. We hypothesized that this phenomenon 
could be explained by the presence of specific variants within the genes involved in phenylalanine transport or in 
the phenylalanine transamination/oxygenation pathway. 
Methods: We selected a clinically homogenous group of 100 infants with PKU and assessed their growth patterns 
in the context of dietary phenylalanine tolerance. Next, within the sample, we performed exome sequencing and 
assessed a potential relationship between the observed phenotypical variability and the presence of structural 
variants in a priori selected genes of interest. 
Results: We detected a highly significant association between overweight and carriership of the rs113883650/ 
rs2287120 haplotype of the SLC7A5 (LAT1) gene, which encodes the main transmembrane transporter of large 
neutral amino acids and of thyroid hormones. 
Conclusions: Our findings suggest a pharmacogenetic effect of the relatively common rs113883650/rs2287120 
haplotype of the SLC7A5 gene. This can have practical implications for patients with PKU, since treatment 
protocols need to be reassessed to better prevent overweight in the carriers of the above variant.   
1. Introduction 
Phenylketonuria (PKU; MIM #261600) is a classic example of a 
monogenic disease with a genetic background that has been extensively 
studied [1–3]. Hyperphenylalaninemia, resulting from deficient activity 
of the enzyme phenylalanine hydroxylase (PAH) in the liver, is the 
major biochemical sign of PKU. The disease can be effectively treated 
with a low-phenylalanine diet [4]. However, the prediction of the 
metabolic phenotype based on individual genotype is not straightfor-
ward, even in patients with a complete absence of the PAH activity. 
Also, the wide genotypic diversity in most populations hinders the 
genotype-phenotype predictions [2,3]. Moreover, although the princi-
ples of treatment are well known, a proportion of patients who adhere 
well to dietary prescriptions tend to become overweight [5–10]. 
Furthermore, blood phenylalanine concentrations do not always re-
spond to the fluctuations of the phenylalanine intake [11,12]. These 
clinical observations suggest that the inconsistencies in the PKU phe-
notype could have a genetic background. This can relate to the trans-
port of phenylalanine between various body compartments or to the 
additional PAH-independent pathways of phenylalanine metabolism 
that might become clinically significant in patients with severe hyper-
phenylalaninemia. 
The transport mechanisms of phenylalanine through the various 
body pools, and its urinary excretion, remain not fully understood 
[13–16]. However, five genes encoding the amino acid transporters are 
known to regulate the transmembrane transport of phenylalanine. 
Namely, the SLC7A5 gene encoding the specific subunit of the LAT1 (L- 
type amino acid transporter 1), which exhibits the highest affinity to 
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the phenylalanine, the SLC7A8 gene (encoding the LAT2 transporter), 
the SLC16A10 gene encoding the TAT1 (T-type amino acid transporter 
1), as well as the SLC43A1, and the SLC43A2 genes encoding the LAT3 
and the LAT4 transporters, respectively. 
The PAH-independent blood phenylalanine clearance is of low ef-
fectiveness [17]. However, the transamination of phenylalanine to 
phenylpyruvate and its further oxygenation should be considered in 
case of significant hyperphenylalaninemia. According to the Kyoto 
Encyclopedia of Genes and Genomes, five genes seem to be important in 
this regard: the IL4I1 gene encoding the L-amino acid oxidase, the 
GOT1 and the GOT2 genes encoding the aspartate aminotransferase, the 
TAT gene encoding the tyrosine aminotransferase, and the HPD gene 
encoding the 4-hydroxyphenylpyruvate dioxygenase [18]. 
Currently, more than 950 pathogenic variants of the PAH gene have 
been described that result in the development of PKU, and most po-
pulations are genetically very heterogeneous [2,3]. Fortunately, the 
Polish population differs with this regard in comparison to the other 
countries, since approximately 40% of patients are homozygous for the 
variant p.Arg408Trp (commonly used name: R408W), which de-
termines the nearly complete absence of the enzymatic activity of PAH 
[19]. 
In the present study, we aimed to assess the potential genetic 
background of the frequent overweight in infants with PKU, in the 
context of the variability of tolerance of dietary phenylalanine. We 
hypothesized that the previously mentioned phenotypic discrepancies 
between the patients could be explained by the presence of specific 
variants within the genes involved in the transmembrane transport of 
phenylalanine or the phenylalanine transamination/oxygenation 
pathway. We hoped that the knowledge gained in our study could 
contribute to the increased precision of dietary treatment strategies, 
and subsequently, could result in better prevention of the overweight in 
PKU. 
2. Patients and methods 
The study was conducted at the Department of Medical Genetics, 
Jagiellonian University Medical College in Krakow, Poland. The pa-
tients were recruited from five regional centers of the metabolic pe-
diatrics in Poland (Krakow, Warsaw, Lodz, Gdansk and Wroclaw), 
which follow approximately 2500 patients with PKU (roughly 60% of 
the PKU population in Poland). In the present study, we only included 
the patients homozygous for the p.Arg408Trp variant (genotype: 
ENST00000553106.5: c.[1222C  >  T];[1222C  >  T]), who were born 
between the years 2000 and 2018. Estimation of sample size revealed 
that statistically significant results could be obtained if at least 86 in-
dividuals are recruited for the study (1-alpha = 95%; 1-beta = 80%; 
ratio of carriers of a gene variant/wild-type individuals = 1; percent of 
unexposed with outcome vs. exposed with outcome 5:30). Given the 
potential necessity for using correction for multiple comparisons, we 
finally recruited one hundred consecutive patients/infants; 47 girls and 
53 boys. 
First, we measured the body weight at birth, after six months of life 
( ± 3 weeks) and at the age of 1 year ( ± 3 weeks). We also measured 
the body length and calculated the body mass index (BMI) after 
6 months of life and at the age of 1 year. For an assessment of the 
growth parameters, we utilized the Z-score (Standard Deviation score) 
and the growth charts recommended for the Polish population [20]. 
Measurements of body weight and of body length were conducted by 
hospital anthropologists or metabolic nurses (body length was mea-
sured with the use of an infant measuring board). 
Next, the dietary phenylalanine tolerance was estimated for all the 
patients by the dieticians taking care of them on an every-day basis. All 
patients were treated with the use of standard dietary protocol: re-
commended blood phenylalanine concentration of 0.12–0.36 mmol/L, 
a daily protein intake of approx. 2.4 g/kg of body weight. Blood phe-
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samples were collected at home by the parents of a child or at the 
outpatient clinic on the occasion of a control visit). During the ob-
servation, the mean blood phenylalanine concentrations remained 
within the recommended range in all patients. Incidental episodes of 
too high or too low concentrations were closely monitored and 
promptly corrected by dieticians taking care of the children. 
For every patient, we calculated daily phenylalanine tolerance at 
the timepoints of the body weight assessment. We also assessed mean 
energy intake, total protein intake, and feeding mode: breast milk or 
infant formula as the source of natural protein. Only breast milk or 
commercially available standard infant formulas constituted the 
sources of natural protein. We assumed that 100 mL of breast milk 
contains 46 mg of phenylalanine. In breastfed infants, the individually 
calculated, appropriate amount of breast milk was mixed with pheny-
lalanine-free formula prior to feeding. We excluded all preterm babies 
and infants with an additional gastrointestinal problem (such as gas-
troesophageal reflux and feeding intolerance) from the analysis. 
Lastly, we assessed the presence of the genetic variants of the se-
lected ten genes: IL4I1, GOT1, GOT2, TAT, HPD, SLC7A5, SLC7A8, 
SLC16A10, SLC43A1, and SLC43A2. The DNA for genotyping was ex-
tracted from the blood leukocytes (the blood samples of 1 mL were 
collected from every patient during the routine control blood tests). The 
MagCore Nucleic Acid Extractor (TK Biotech, Warsaw, Poland) was 
utilized for the extraction. Subsequently, 100 ng of genomic DNA of 
every sample was enzymatically fragmented (as determined at Sure 
Select XT and XT Low Input Enzymatic Fragmentation Protocol, Agilent 
Technologies, Santa Clara, USA) and used for exome library preparation 
according to the SureSelectXT HS Target Enrichment System for 
Illumina Paired-End Multiplexed Sequencing Library protocol (Agilent 
Technologies). Next, the libraries were tagged, pooled, and prepared for 
sequencing. Finally, the sequencing of the libraries was performed by 
an external genotyping service provider (Macrogen Europe, 
Netherlands) with the use of the NovaSeq 6000 genomic sequencer. The 
genotyping findings were confirmed with the use of classic sequencing 
(the Sanger's method). 
The raw genotyping data were processed with the use of the 
DRAGEN Enrichment software (Illumina, San Diego, USA) in order to 
obtain a table of all genetic variants in every patient. However, the final 
data analysis was restricted only to the a priori selected set of ten genes 
encoding the phenylalanine transmembrane transporters and the en-
zymes of the phenylalanine transamination/oxygenation pathway. We 
also excluded rare genetic variants from the statistical analysis and 
focused only on those variants revealing the allelic frequency above 
1%. 
Finally, within the sample, we evaluated the presence of potential 
associations of the specific gene variants with the body weight and the 
phenylalanine tolerance. For the statistical analysis, we used descriptive 
statistics, the Pearson correlation and the t-test with a Bonferroni cor-
rection for multiple comparisons. 
The study procedure was approved by the Jagiellonian University 
Ethics Committee (approval No. 1072.6120.9.2019). Informed consent 
form was obtained from the parents of the study participants. 
3. Results 
We assessed a group of 100 patients (47 girls and 53 boys). There 
were no apparent differences in the body weight in comparison to the 
general population of term babies at birth. The mean body weight 
equaled 3348 g (−0.15 SD) in girls and 3542 g (+0.12 SD) in boys. 
However, the mean body weight increased visibly for the entire group, 
reaching 7984 g (+0.59 SD) in girls and 8616 g (+0.49 SD) in boys at 
the age of six months. At the age of 1 year, the mean body weight 
equaled 10,456 g (+0.8 SD) in girls and 10,649 g (+0.26 SD) in boys. 
The mean Body Mass Index (BMI) value reached 17.84 (+0.89 SD) in 
girls at 6 months and 18.32 (+0.88 SD) at 1 year, whereas in boys the 
values were 18.36 (+0.89 SD) and 18.38 (+0.71 SD) after 6 months of 
life and 1 year, respectively. This suggests the presence of a tendency to 
develop overweight in some infants with PKU, especially during the 
first 6 months of life. 
In our patients, the mean daily phenylalanine tolerance at the time 
point of the introduction of the therapeutic low-phenylalanine diet 
(first month of life) reached 138 mg (85–211 mg; 23–58 mg/kg). 
Subsequently, it increased to 275 mg (188–432 mg; 22–48 mg/kg) at 
the age of 6 months and remained nearly unchanged in the next 
6 months, reaching 278 mg (214–389 mg; 19–36 mg/kg, mean 
26.3 mg/kg) at the age of 1 year. Pearson correlation revealed that the 
total daily tolerance in the assessed infants positively correlated with 
their body weight in the first month of life: r = 0.42, p = 0.000 (sig-
nificant at 0.01 level, 2-tailed), as well as in the sixth month of life: 
r = 0.44, p = 0.000 (significant at 0.01 level, 2-tailed). 
The assessment of the feeding type revealed that breastmilk was a 
source of natural protein in 29% infants, and formula in the remaining 
71% of patients. We did not observe any significant associations of the 
body growth dynamics or the phenylalanine tolerance neither with the 
type of feeding in study participants, nor with the phenylalanine tol-
erance. 
Based on the above findings, in the final data analysis, we focused 
on two most interesting variables: body weight in the sixth month of 
Fig. 1. Differences in standard deviation scores for the body weight between wild-type individuals and carriers of the rs113883650/rs2287120 haplotype at the age 
of 6 months. 
The wild-type individuals are displayed on the left, and the carriers on the right. The carriers were, on average, much heavier. The difference in standardized body 
weight (SD score) was highly significant, as indicated by the p-value of 0.002 obtained by utilizing the Bonferroni correction for multiple comparisons. The pink and 
blue dots represent the girls and boys, respectively. Homozygotes are indicated by larger dots. 
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life, when the apparent increase in average body weight was first ob-
served, and dietary phenylalanine tolerance (mg/kg of body weight) at 
treatment initiation, reflecting the biggest observed interindividual 
differences in patients. We further analyzed potential associations of 
these two variables with the detected gene variants. 
The sequencing of coding regions of the ten targeted genes identi-
fied 34 variants with an allelic frequency above 1%, which were further 
statistically evaluated. Among the variants of the SLC7A5 gene, we 
identified two variants that are in complete linkage disequilibrium: 
rs113883650 and rs2287120 [21]. 
Among the analyzed 34 variants, an independent t-test revealed that 
there was a highly significant difference between the standardized (SD 
score) body weight of the carriers of the rs113883650/rs2287120 
haplotype (1.12  ±  1.17) and individuals with the wild-type genotype 
of the SLC7A5 gene (0.07  ±  1.20) at the age of six months (t 
(98) = −4.33, p = 0.00003), with the difference of −1.045 (95% CI, 
−1.522 to −0.568). The Bonferroni correction for multiple compar-
isons yielded a p-value of 0.002. The carriers of the above haplotype at 
the age of six months were, on average, much heavier than the wild- 
type individuals. Details on the detected gene variants can be found in  
Table 1. 
Supplementary Body Mass Index analyses confirmed a clear ten-
dency to become overweight in carriers. At the age of six 6, the average 
BMI in girls reached 19.1 in carriers vs. 17.39 in wild-type individuals 
(+1.84 SD vs. +0.56 SD), whereas in boys, the average BMI values 
were 19.39 vs. 18.00 (+1.7 SD vs. +0.62 SD), respectively. This ten-
dency persisted at the age of 1 year. A detailed assessment of body 
weight and BMI with regards to the gender of study participants and to 
carriership of the rs113883650/rs2287120 haplotype can be found in  
Table 2, Fig. 1, and Fig. 2. 
Fig. 2. Body weight in grams at birth and at the age of 6 months, as well as body length at the age of 6 months in wild-type individuals and in carriers of the 
rs113883650/rs2287120 haplotype. 
The wild-type individuals are displayed on the left, and the carriers on the right. As can be seen, there were no visible differences in body weight at birth. However, 
differences in body weight became apparent at the age of 6 months (upper and middle parts of the figure), contrary to body length (lower part of the figure). The pink 
and blue dots represent the girls and boys, respectively. Homozygotes are indicated by larger dots. 
M. Bik-Multanowski, et al.   Molecular Genetics and Metabolism Reports 25 (2020) 100640
5
Assessment of the potential associations of the differences in the 
phenylalanine tolerance with the presence of the detected gene variants 
did not reveal any statistically significant findings. Also, the carriers of 
the rs113883650/rs2287120 haplotype did not differ significantly from 
wild-type individuals with regard to their mean daily intake of energy 
and of total protein, as estimated for the period from the end of the first 
month of life until the age of 6 months (116 kcal/kg versus 114 kcal/kg 
and 2.38 g/kg versus 2.39 g/kg, respectively). Data on individual pa-
tients can be found in Table 3. 
4. Discussion 
In the present study, we detected a clear tendency to develop 
overweight in patients with PKU, who are carriers of two coinherited 
Table 3 
The mean individual daily intake of energy, protein and phenylalanine. The values were calculated for the period from the end of the first to the end of the sixth 
month of life.          
Patient Energy (kcal/kg) Total protein (g/kg) Phenylalanine (mg/kg) Patient Energy (kcal/kg) Total protein (g/kg) Phenylalanine (mg/kg) 
Wild-type individuals 
Girls Boys  
1 106 2.2 47 30 127 2.5 40 
2 112 2.2 40 31 94 2.1 32 
3 112 2.4 44 32 94 2.2 39 
4 116 2.3 36 33 119 2.5 40 
5 108 2.1 44 34 101 2.3 38 
6 114 2.5 47 35 113 2.4 50 
7 124 2.3 50 36 107 2.6 34 
8 114 2.5 37 37 123 2.9 44 
9 113 2.3 55 38 108 2.6 40 
10 108 2.4 36 39 128 2.4 33 
11 110 2.6 40 40 113 2.5 35 
12 113 2.4 39 41 91 1.8 44 
13 104 2.5 34 42 119 2.5 49 
14 121 2.6 42 43 102 2.5 55 
15 114 2.9 49 44 121 2.5 33 
16 113 2.4 49 45 105 2.2 30 
17 108 2.4 36 46 110 2 53 
18 116 2.4 36 47 108 2.5 37 
19 130 2.5 45 48 124 2.4 45 
20 113 2.4 38 49 109 2.6 50 
21 120 2.5 40 50 113 2.4 39 
22 113 2.4 30 51 115 2.1 36 
23 111 2.6 28 52 116 2.3 43 
24 121 2.5 36 53 116 3 45 
25 119 2.3 35 54 98 1.9 35 
26 114 2.4 46 55 115 2.1 38 
27 108 2.3 42 56 108 2.1 38 
28 108 2.4 38 57 114 2.4 50 
29 117 2.4 49 58 128 2.3 42     
59 106 2.3 45           
Carriers of the rs113883650/rs2287120 haplotype 
Girls Boys  
60 116 2.4 50 78 112 2.6 35 
61 117 2.3 39 79 117 2.3 38 
62 110 2.3 40 80 114 2.5 55 
63 114 2.3 30 81 117 2.2 42 
64 112 3 37 82 128 2.6 35 
65 112 2.4 36 83 130 2.4 50 
66 115 2.4 30 84 113 2.3 38 
67 113 2.3 42 85 130 2.5 50 
68 115 2.5 44 86 115 2.3 40 
69 108 2.2 37 87 91 2.2 38 
70 115 2.4 29 88 106 2.4 32 
71 127 2.4 44 89 125 2.2 57 
72 114 2.3 46 90 115 2.1 35 
73 105 2.4 36 91 104 2.4 48 
74 122 3 36 92 115 2.3 45 
75 97 2.3 36 93 100 2.4 36 
76 123 2.4 38 94 130 2.3 52 
77 120 2.2 37 95 96 2.1 36     
96 120 2.5 40     
97 120 2.1 41     
98 119 2.3 52     
99 115 2.4 45     
100 114 2.6 34    
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variants of the SLC7A5 gene: rs113883650 and rs2287120. The protein 
encoded by the SLC7A5 gene – the L-type amino acid transporter 1 
(LAT1) binds to the SLC3A2 to form a heterodimer. This heterodimer 
functions as the master transmembrane transporter of phenylalanine 
and other large neutral amino acids: tyrosine, leucine, histidine, me-
thionine and tryptophan [22–26]. The transporter is expressed in most 
tissues, especially in the cerebral cortex, the blood-brain barrier, the 
bone marrow, the gastrointestinal tract, the placenta, and in several 
cancers [24,27–30]. 
The rs113883650 variant is a deletion of five nucleotides (ATATG) 
located in intron 3 (ENSG00000103257; position 16: 
87840502–87,840,508), within a close distance to the fourth exon. 
Interestingly, this genomic region seems to have a regulatory function 
with regard to gene expression as it encodes a binding site for the 
transcriptional repressor CTCF that regulates the 3D structure of chro-
matin. CTCF is thought to be a primary part of the activity of insulators, 
sequences that block the interaction between enhancers and promoter 
regions [31]. The rs2287120 variant is a single nucleotide poly-
morphism (G  >  A substitution) and is located in intron 6, near the 
start of exon 7 (ENSG00000103257; position 16:87837976). Both var-
iants are located 2526 nucleotides from each other. 
Our results strongly suggest the presence of a functional alteration 
in the SLC7A5 gene in the carriers of the rs113883650/rs2287120 
haplotype. However, it is not clear how the pathomechanism of be-
coming overweight could be related to the function of the gene. 
Overweight and obesity represent key medical problems. 
Overweight can result from increased caloric intake, and in patients 
with inborn errors of metabolism, who are treated with the use of 
specific diets, the risk of overweight might increase due to inadequate 
metabolic control. However, experienced dietitians closely supervised 
the treatment in our patients and ensured that the diet was properly 
controlled. It should also be noted that all members of the metabolic 
teams used only one, common treatment protocol. Finally, the mean 
daily energy intake, as well as mean total protein and phenylalanine 
intakes, were nearly identical in carriers of the rs113883650/ 
rs2287120 haplotype and in wild type individuals. Therefore, the 
dietary imbalance as a reason for becoming overweight seems to be 
unlikely in our patients. Similarly, the observed overweight can hardly 
be attributed to the alteration of the capacity of the SLC7A5/SLC3A2 
complex for the transmembrane transport of neutral amino acids, which 
might potentially affect their incorporation into the body proteins and 
increase their conversion to the body fat. 
However, the SLC7A5/SLC3A2 complex also mediates the transport 
of other biologically important substances: the thyroid hormones – 
triiodothyronine (T3) and thyroxine (T4), as well as the transport of 
several widely used and clinically important drugs (e.g., the anti-
parkinsonian drug L-Dopa, the anticancer drug melphalan and the an-
tiepileptic drug gabapentin) [32–36]. Since the action of thyroid hor-
mones is intracellular, alteration of their cellular uptake can alter the 
thyroid-dependent cellular metabolism and the basal metabolic rate, 
which might eventually lead to body weight increase. In this context, 
the presence of the rs113883650 variant that is localized in a reg-
ulatory, CTCF-binding region of the SLC7A5 gene might have resulted 
in a functional alteration of the entire SLC7A5/SLC3A2 complex and in 
the observed tendency to overweight in our patients. 
The carriership of the rs113883650/rs2287120 haplotype is 
common, and its potential association with overweight/obesity or with 
alteration of the homeostasis of thyroid hormones should have been 
detected in the previous genome-wide association studies in adult and 
pediatric populations [37–40]. However, that did not happen. Never-
theless, additional factors make this situation more complex and should 
be considered. First, the cohort assessed in our study represents a group 
of young infants, who typically double their birth weight within the 
first 5 to 6 months of life. Even a subtle metabolic alteration in this 
period of very dynamic growth might significantly affect the weight 
gain. Moreover, feeding mode is similar in all young infants. Thus, the 
tendency to develop overweight in the carriers of the rs113883650/ 
rs2287120 haplotype should be more clearly visible in this period of 
time in comparison to adults, who have their own individual dietary 
preferences and who can actively modify their body weight. Secondly, 
PKU is a rare disease that is genetically and clinically very heterogenic 
[2,3]. The previous studies on overweight in PKU included patients 
with various genotypes, disease severity, those following different 
dietary treatment regimens, and members of various age groups [6]. On 
the contrary, we selected a relatively large group of patients, who were 
homozygous for the most common pathogenic variant of PAH 
(p.Arg408Trp), belonged to one age group, and who could be precisely 
monitored with regard to their diet by dieticians. This approach al-
lowed us to detect statistically significant genotype-phenotype corre-
lations in relation to the a priori selected set of genes that could alter 
PAH-independent phenylalanine disposal in the body. Lastly, the 
rs113883650 variant might be of functional importance only in in-
dividuals with PKU, in whom blood phenylalanine concentrations are 
always well above the physiologic level. This is because hyperpheny-
lalaninemia competitively blocks the SLC7A5/SLC3A2 complex-medi-
ated transport of thyroid hormones [32]. Therefore, any subclinical 
alteration of cellular uptake of thyroid hormones in patients with PKU 
could be potentiated in carriers of the rs113883650 variant. On the 
contrary, hyperphenylalaninemia is not observed in persons not af-
fected with PKU, and the functional effect of the rs113883650 variant 
should most probably be absent in them. 
Future studies on cellular uptake of thyroid hormones in fibroblasts 
exposed to hyperphenylalaninemia could aim to verify the functional 
role of the rs113883650 variant of the SLC7A5 gene. 
We observed a fair association between phenylalanine tolerance and 
body weight. This correlation is expected and seems to reflect the body 
mass-related net protein catabolism-synthesis ratio. However, the ob-
served large interindividual differences in phenylalanine tolerance 
suggest that additional factors might be responsible for this variability. 
Previous observations of the significant differences in the blood and 
urine concentrations of the phenylalanine transamination/oxygenation 
metabolites (phenylpyruvic acid, phenyllactic acid and hydro-
xyphenylacetic acid) in patients with similar blood phenylalanine 
concentrations seem to support this hypothesis [14]. However, it should 
be noted that the above-mentioned differences were observed mostly in 
patients with very high hyperphenylalaninemia, whereas in the parti-
cipants within our study the blood phenylalanine concentration was 
carefully monitored. Therefore, further studies with patients with var-
ious severity of hyperphenylalaninemia are needed in order to explore 
the potential genetic background of the various tolerance of dietary 
phenylalanine. 
Some limitations of the present study should be mentioned. We did 
not use any control population. Assessment of the growth dynamics of 
healthy infants could help to eliminate the bias related to potential 
dietary imbalance during the treatment of infants with PKU. Also, we 
did not assess patients from other countries, which could be useful to 
exclude any unexpected population-specific or region-specific genetic 
or epigenetic effects. The above issues can be addressed in further, 
confirmatory studies in larger populations. 
5. Conclusions 
Our study demonstrates a clinically relevant association between 
developing overweight in patients with PKU and the carriership of the 
common rs113883650/rs2287120 haplotype of the SLC7A5 gene en-
coding the L-type amino acid transporter 1. Our findings might have 
potential practical implications for children with PKU, since treatment 
protocols need to be reassessed to better prevent overweight in the 
carriers of the above gene variant. 
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